Biovance was originally developed by, and is currently being manufactured through a supply agreement with, Celgene Cellular Therapeutics (CCT), a subsidiary of Celgene, to assist wound care specialists, physicians and nurses, as well as vascular, plastic and general surgeons, in the treatment of a wide variety of complex, acute, chronic, recalcitrant, full and partial thickness wound types.

With the right to develop and market Biovance, Alliqua has entered into one of the fastest-growing areas of wound care, which involves regenerative medicine. Alliqua will commence sales of Biovance immediately following the Symposium via its team of direct sales representatives.

Additionally, Dr Terry Treadwell and Donna Walker, LPN (Institute for Advanced Wound Care, Montgomery, AL) have authored a poster that will be on display during SAWC (CR_049) titled ‘Treatment of Second Degree Burns with Dehydrated, Decellularized Amniotic Membrane (Biovance) versus a Nanocrystalline Silver Dressing’.

The poster reviews time to healing and visual cosmetic appearance of the burn scar with Biovance compared to silver dressing in patients with second-degree burns.

On April 14, 2014, Celgene invested $5,000,000 in Alliqua as part of the company’s previously announced private placement that resulted in gross proceeds to the company of $15m.

Alliqua CEO David Johnson noted that the SAWC meeting is the ideal venue at which to launch the company’s Biovance product and to convey its natural benefits to the wound care community.

"The launch of Biovance marks a major milestone for Alliqua, representing a key application of regenerative medicine for advanced wound care and an important addition to Alliqua’s wound care portfolio. We are confident that wound care specialists and their patients will be impressed with the value this human amniotic membrane allograft brings to their wound care arsenal," Johnson added.